---
title: "Antibody discovery platform Immunocan closes RMB250 million Series A"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286186107.md"
description: "Shanghai-based Immunocan has successfully closed a RMB250 million Series A funding round, led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing investors like Kingray Capital and TigerYeah Capital. The funds will be utilized to enhance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, develop an AI-driven antibody drug screening platform, and expand its team. Founded in 2020, Immunocan specializes in antibody discovery using gene-editing technologies and collaborates with various pharmaceutical companies globally."
datetime: "2026-05-13T02:39:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286186107.md)
  - [en](https://longbridge.com/en/news/286186107.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286186107.md)
generator: "portal-rs"
---

# Antibody discovery platform Immunocan closes RMB250 million Series A

Shanghai-based Immunocan has closed a RMB250 million Series A round led by Vivo Capital, with participation from Gold Mine Multi Family Office and follow-on backing from existing investors including Kingray Capital and TigerYeah Capital. The company said the funds will be used to advance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, build an AI-driven antibody drug screening platform, and expand its team.

Founded in 2020, Immunocan develops antibody discovery platforms based on gene-editing technologies. The company said it has built a multi-species platform portfolio spanning mouse, alpaca, and rabbit models, while also advancing its MabAI platform for AI-based antibody generation and characterization. Immunocan added that it is already working with multiple domestic and international pharmaceutical companies, including several top global drugmakers. \[TechNode reporting\]

### Related Stocks

- [300347.CN](https://longbridge.com/en/quote/300347.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [513290.CN](https://longbridge.com/en/quote/513290.CN.md)

## Related News & Research

- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/en/news/280923090.md)
- [Daiwa Raises TIGERMED  to Buy, Cuts TP to HKD44](https://longbridge.com/en/news/292006063.md)
- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)
- [Everest’s US$250 million buy signals rising global appetite for China biotech](https://longbridge.com/en/news/282130717.md)
- [08:33 ETDrugwatch Investigation Reveals Big Pharma Profits Continue to Outpace Billions in Legal Penalties](https://longbridge.com/en/news/281368752.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**